Parnax Lab Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L36912MH1982PLC027925 Incorporated 03 August 1982 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: PARNAXLAB · BSE: 506128 Public Limited Company pharma
Market Cap
₹132 Cr
PARNAXLAB · NSE
Share Price
₹116.42
+1.66% today
Revenue
₹249 Cr
FY 2025-26 · +32.4% YoY
EBITDA
₹25.88 Cr
Margin 10.4%
Net Profit
₹12.80 Cr
FY 2025-26 · +9.3% YoY
P/E (TTM)
14.5x
P/B 1.3x
ROE
13.2%
ROCE 13.0%
Debt / Equity
0.85
Interest cover 32.0x

About Parnax Lab Limited

Data last updated:

Parnax Lab Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 August 1982 and has been in existence for over 44 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L36912MH1982PLC027925. Its GSTIN is 27AAACK1457E1ZT (Maharashtra). The company holds 3 GST registrations, of which 2 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 506128 and NSE: PARNAXLAB.

The company has an authorised share capital of ₹13 Cr and a paid-up capital of ₹11.49 Cr. It was formerly known as Krishna-Deep Trade and Investment Ltd. It is led by directors including Mihir Prakash Shah (Managing Director) and Ami Mihir Shah.

Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Gala No. 114 Bldg. No. 8 Jogani Industrial Complex Chunabhatti, Mumbai, Maharashtra, India – 400022.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹248.54 Cr, a growth of 32.4% compared to the previous year. For the same year it recorded a net profit of ₹12.8 Cr (net margin 5.2%) and EBITDA of ₹25.88 Cr (EBITDA margin 10.4%). The net worth stands at ₹95.14 Cr (up 14.5% YoY). Total assets are valued at ₹179.22 Cr (up 16.8% YoY).

Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Naxpar Group. As per MCA filings, the company has open charges of ₹24.2 Cr and satisfied charges of ₹4.66 Cr on record. Court records list 1 case involving the company, including 1 filed by the company. The company has 150 deals on record (148 market trades, 2 funding rounds), with disclosed funding of ₹24.01 Cr; the latest was in March 2022. Its 7 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 4 smaller; the largest is Galentic Pharma India Pvt Ltd with revenue of ₹195.24 Cr. The company has 14 MSME Form 1 returns on record between 2019 and 2024, listing 283 overdue payments to 41 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website naxparlab.com.

Company details

CIN L36912MH1982PLC027925
Registration Number 027925
Incorporation Date 03 August 1982
ROC Mumbai
Listing Status Listed - Listed on NSE (PARNAXLAB); Listed on BSE (506128)
Company Status Active
Compliance Status Active Compliant

CIN history

Parnax Lab has one previous CIN (Corporate Identification Number): L67120MH1982PLC027925. The current CIN is L36912MH1982PLC027925, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L36912MH1982PLC027925Current
L67120MH1982PLC027925Previous

Contact details

Parnax Lab Limited's registered office is in Mumbai, Maharashtra. Its website is naxparlab.com. Its e-mail address is in the company report.

  • Email
  • Registered Address
    Gala No. 114 Bldg. No. 8 Jogani Industrial Complex Chunabhatti, Mumbai, Maharashtra, India – 400022
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Parnax Lab Limited, buy the company report.

Comprehensive company report
Parnax Lab Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Parnax Lab operates one associated brand: Naxpar Group. Each brand links to its own profile.

BrandDescriptionWebsite
Pharmaceutical, cosmetic, herbal, and nutraceutical formulations are manufactured.naxparlab.com

Business activity

The main business activity of Parnax Lab is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Parnax Lab Limited, buy the company report.

Financials of Parnax Lab Limited

FY 2025-26 filings available

Parnax Lab Limited reported revenue of ₹248.54 Cr (up 32.4% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹249 Cr
+32.4% YoY
EBITDA
₹25.88 Cr
-3.3% YoY
Profit After Tax
₹12.80 Cr
+9.3% YoY
Net Worth
₹95.14 Cr
+14.5% YoY
Total Assets
₹179 Cr
+16.8% YoY
Total Debt
₹82.79 Cr
+19.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue24918818916816390.0695.31
Revenue growth+32.4%-0.5%+12.6%+2.8%+81.0%-5.5%-
EBITDA25.8826.7723.5522.9923.039.946.43
EBITDA margin+10.4%+14.3%+12.5%+13.7%+14.1%+11.0%+6.8%
Profit before tax15.9015.6812.0612.2812.26(0.09)(1.97)
Net profit12.8011.719.608.618.23(0.38)(2.92)
Net profit margin+5.2%+6.2%+5.1%+5.1%+5.1%-0.4%-3.1%
EPS (₹)10.2710.038.377.508.40(0.43)(3.43)
Balance sheet
Total assets17915315311711891.7884.37
Net worth95.1483.1071.5862.1648.1832.5432.79
Total debt82.7969.5380.6454.7269.0858.9051.23
Cash & bank2.262.681.882.785.781.271.30
Net working capital48.2033.7240.6933.6638.5626.6324.51
Cash flow
Cash from operations8.0032.3015.8820.918.556.318.75
Cash from investing(16.39)(16.39)(31.52)(9.92)(16.50)(6.56)(13.33)
Cash from financing8.18(15.82)14.82(14.07)12.130.055.03
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue69.2656.8069.6362.9462.6053.3849.0440.22
Revenue growth (YoY)+10.6%+6.4%+42.0%+56.5%+29.5%+6.5%--
Other income0.210.151.990.970.630.180.430.19
EBITDA6.904.304.665.718.087.446.634.28
EBITDA margin+10.0%+7.6%+6.7%+9.1%+12.9%+13.9%+13.5%+10.6%
Depreciation2.332.222.041.962.101.941.831.79
Interest1.601.641.611.471.401.221.281.23
Profit before tax3.180.593.003.255.214.463.951.45
Tax0.990.170.810.541.581.181.030.24
Net profit2.190.422.192.713.633.282.921.21
EPS (₹)1.900.371.902.373.152.852.551.06
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6.637.027.447.477.152.377.68
Revenue growth-5.6%-5.7%-0.4%+4.5%+201.7%-69.1%-
EBITDA(1.62)1.242.091.561.37(0.45)0.55
EBITDA margin-24.4%+17.7%+28.1%+20.9%+19.2%-19.0%+7.2%
Profit before tax0.661.872.431.610.78(1.25)(0.45)
Net profit0.931.411.811.190.54(1.13)(1.99)
Net profit margin+14.0%+20.1%+24.3%+15.9%+7.6%-47.7%-25.9%
EPS (₹)0.771.211.591.050.55(1.33)(2.36)
Balance sheet
Total assets23.4522.5721.1820.4421.9516.1416.90
Net worth23.4222.5521.1619.3612.754.715.82
Total debt0.000.000.001.079.2011.4111.06
Cash & bank1.101.280.461.284.350.110.12
Net working capital10.838.966.965.576.584.185.18
Cash flow
Cash from operations(0.72)0.280.08(0.28)(0.36)0.472.20
Cash from investing0.57(0.19)0.300.140.000.00(0.01)
Cash from financing(0.03)(0.02)(1.21)(2.92)4.59(0.48)(1.55)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue0.532.570.252.711.701.970.840.99
Revenue growth (YoY)-68.8%+30.5%-70.2%+173.7%+10.4%-46.2%--
Other income0.200.211.760.220.200.190.190.17
Total expenses0.861.913.271.961.201.811.120.92
EBITDA(0.33)0.66(3.02)0.750.500.16(0.28)0.07
EBITDA margin-62.3%+25.7%-1208.0%+27.7%+29.4%+8.1%-33.3%+7.1%
Depreciation0.020.020.020.020.020.020.020.02
Interest0.000.000.010.000.020.010.010.01
Profit before tax(0.15)0.85(1.29)0.950.660.32(0.12)0.21
Tax0.110.00(0.73)0.240.170.08(0.03)0.05

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 18 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue69.2656.8069.6362.9462.6053.3849.0440.22
Revenue growth (YoY)+10.6%+6.4%+42.0%+56.5%+29.5%+6.5%--
Other income0.210.151.990.970.630.180.430.19
EBITDA6.904.304.665.718.087.446.634.28
EBITDA margin+10.0%+7.6%+6.7%+9.1%+12.9%+13.9%+13.5%+10.6%
Depreciation2.332.222.041.962.101.941.831.79
Interest1.601.641.611.471.401.221.281.23
Profit before tax3.180.593.003.255.214.463.951.45
Tax0.990.170.810.541.581.181.030.24
Net profit2.190.422.192.713.633.282.921.21
EPS (₹)1.900.371.902.373.152.852.551.06
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue24918818916816390.0695.31
Revenue growth+32.4%-0.5%+12.6%+2.8%+81.0%-5.5%-
Other income3.781.680.820.770.330.210.66
Total expenses22316116514514080.1288.88
Employee cost0.0024.4323.7220.0517.4313.6814.08
EBITDA25.8826.7723.5522.9923.039.946.43
EBITDA margin+10.4%+14.3%+12.5%+13.7%+14.1%+11.0%+6.8%
Depreciation8.057.386.966.535.875.164.46
Interest5.715.395.354.955.235.084.60
Profit before tax15.9015.6812.0612.2812.26(0.09)(1.97)
Tax4.104.142.423.654.010.280.95
Net profit12.8011.719.608.618.23(0.38)(2.92)
Net profit margin+5.2%+6.2%+5.1%+5.1%+5.1%-0.4%-3.1%
EPS (₹)10.2710.038.377.508.40(0.43)(3.43)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.4911.4911.4911.499.818.508.50
Reserves & surplus83.6571.6160.0950.6736.5524.0424.29
Shareholders' funds (net worth)95.1483.1071.5862.1648.1832.5432.79
Minority interest0.160.140.120.110.090.080.07
Secured loans45.5828.5238.8522.7227.4821.5429.65
Unsecured loans37.2141.0141.7932.0041.6037.3621.58
Total debt82.7969.5380.6454.7269.0858.9051.23
Total liabilities17915315311711891.7884.37
Assets
Gross block16112912710897.2579.4072.73
Net block11588.2689.4876.8071.9559.6757.68
Capital work in progress11.2929.4420.612.333.344.912.91
Investments0.160.160.160.160.220.220.22
Inventories36.2225.7729.9321.6919.9310.7911.15
Sundry debtors37.8130.7632.5627.8938.0816.7123.08
Cash & bank balances2.262.681.882.785.781.271.30
Loans & advances14.395.568.944.967.2410.4710.08
Total current assets90.6864.7773.3157.3271.0339.2445.61
Total current liabilities42.4831.0532.6223.6632.4712.6121.10
Net working capital48.2033.7240.6933.6638.5626.6324.51
Total assets17915315311711891.7884.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.550.461.284.360.180.39(0.05)
Net cash from operating activities8.0032.3015.8820.918.556.318.75
Net cash from investing activities(16.39)(16.39)(31.52)(9.92)(16.50)(6.56)(13.33)
Net cash from financing activities8.18(15.82)14.82(14.07)12.130.055.03
Net change in cash(0.21)0.09(0.82)(3.08)4.18(0.21)0.44
Closing cash2.262.681.882.785.781.271.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+32.4%-0.5%+12.6%+2.8%+81.0%-5.5%-
EBITDA growth-3.3%+13.7%+2.4%-0.2%+131.7%+54.6%-
PBT growth+1.3%+30.0%-1.8%+0.2%+9998.0%+95.4%-
Net income growth+9.3%+22.0%+11.5%+4.6%+2265.8%+87.0%-
Revenue CAGR (3Y)+14.0%+4.8%+28.0%+20.7%+14.4%-5.1%+0.2%
EBITDA CAGR (3Y)+4.0%+5.1%+33.3%+52.9%+31.1%+0.2%-21.0%
Profitability & leverage
Net income margin+4.7%+6.2%+5.1%+5.2%+5.1%-0.4%-3.1%
Return on capital employed+13.0%+13.8%+12.9%+14.7%+16.7%+5.7%+3.2%
Return on net worth+13.2%+14.9%+14.4%+15.6%+20.5%-1.1%-8.5%
Debt / equity0.850.971.011.121.591.691.36
Long-term debt / equity0.310.360.340.330.470.570.53
Interest cover32.0427.8032.2530.0730.48106.28233.50
Efficiency & per share
Fixed asset turnover1.711.471.611.631.851.181.42
Inventory turnover8.026.747.318.0510.618.219.72
Debtors turnover7.255.936.245.085.954.534.51
EPS (₹)10.2510.038.377.508.40(0.43)(3.43)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)82.8372.3562.3254.1147.2438.2638.56
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue0.532.570.252.711.701.970.840.99
Revenue growth (YoY)-68.8%+30.5%-70.2%+173.7%+10.4%-46.2%--
Other income0.200.211.760.220.200.190.190.17
Total expenses0.861.913.271.961.201.811.120.92
EBITDA(0.33)0.66(3.02)0.750.500.16(0.28)0.07
EBITDA margin-62.3%+25.7%-1208.0%+27.7%+29.4%+8.1%-33.3%+7.1%
Depreciation0.020.020.020.020.020.020.020.02
Interest0.000.000.010.000.020.010.010.01
Profit before tax(0.15)0.85(1.29)0.950.660.32(0.12)0.21
Tax0.110.00(0.73)0.240.170.08(0.03)0.05
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6.637.027.447.477.152.377.68
Revenue growth-5.6%-5.7%-0.4%+4.5%+201.7%-69.1%-
Other income2.370.710.540.370.160.070.42
Total expenses8.255.785.355.915.782.827.13
Employee cost0.000.900.740.550.520.450.51
EBITDA(1.62)1.242.091.561.37(0.45)0.55
EBITDA margin-24.4%+17.7%+28.1%+20.9%+19.2%-19.0%+7.2%
Depreciation0.060.060.060.070.040.040.04
Interest0.030.020.140.250.710.831.38
Profit before tax0.661.872.431.610.78(1.25)(0.45)
Tax(0.24)0.460.620.420.24(0.12)1.53
Net profit0.931.411.811.190.54(1.13)(1.99)
Net profit margin+14.0%+20.1%+24.3%+15.9%+7.6%-47.7%-25.9%
EPS (₹)0.771.211.591.050.55(1.33)(2.36)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.4911.4911.4911.499.818.508.50
Reserves & surplus11.9311.069.677.871.12(3.79)(2.68)
Shareholders' funds (net worth)23.4222.5521.1619.3612.754.715.82
Secured loans0.000.000.001.071.892.632.77
Unsecured loans0.000.000.000.007.318.788.29
Total debt0.000.000.001.079.2011.4111.06
Total liabilities23.4522.5721.1820.4421.9516.1416.90
Assets
Gross block1.081.051.050.920.870.870.87
Net block0.390.430.490.430.440.480.53
Capital work in progress0.000.000.000.000.000.000.00
Investments10.0310.0310.0310.0310.0710.0710.07
Inventories0.800.780.900.580.790.580.15
Sundry debtors0.420.850.591.081.860.432.06
Cash & bank balances1.101.280.461.284.350.110.12
Loans & advances9.517.796.083.561.164.564.60
Total current assets11.8310.708.036.508.165.686.93
Total current liabilities1.001.741.070.931.581.501.75
Net working capital10.838.966.965.576.584.185.18
Total assets23.4522.5721.1820.4421.9516.1416.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.500.441.274.330.100.11(0.53)
Net cash from operating activities(0.72)0.280.08(0.28)(0.36)0.472.20
Net cash from investing activities0.57(0.19)0.300.140.000.00(0.01)
Net cash from financing activities(0.03)(0.02)(1.21)(2.92)4.59(0.48)(1.55)
Net change in cash(0.18)0.06(0.83)(3.07)4.23(0.01)0.64
Closing cash1.101.280.461.284.350.110.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-5.6%-5.7%-0.4%+4.5%+201.7%-69.1%-
EBITDA growth-230.7%-40.7%+34.0%+13.9%+404.4%-181.8%-
PBT growth-64.9%-22.6%+50.9%+106.4%+9998.0%-177.8%+13.5%
Net income growth-34.0%-22.1%+52.1%+120.4%+147.8%+43.2%-
Revenue CAGR (3Y)-3.9%-0.6%+46.4%-0.9%+3.3%-25.8%+13.3%
EBITDA CAGR (3Y)--3.0%-+41.6%+139.3%-26.0%-4.9%
Profitability & leverage
Net income margin+13.6%+20.2%+24.3%+15.9%+7.6%-47.7%-25.8%
Return on capital employed+2.4%+6.7%+9.1%+6.2%+6.2%0.0%0.0%
Return on net worth+3.2%+5.0%+6.5%+4.8%+4.0%0.0%0.0%
Debt / equity0.000.000.030.321.182.131.63
Long-term debt / equity0.000.000.000.040.170.440.42
Interest cover-1.791.686.9016.7853.38-169.39270.59
Efficiency & per share
Fixed asset turnover6.236.697.558.358.222.728.83
Inventory turnover8.398.3610.0510.9110.446.4926.95
Debtors turnover10.449.758.915.086.241.903.37
EPS (₹)0.771.211.591.050.55(1.33)(2.36)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)20.3919.6318.4216.8511.145.546.85

To see the full year-wise statements and ratios of Parnax Lab Limited, buy the company report.

Board of directors of Parnax Lab Limited

Parnax Lab has 6 current directors and 15 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Ami Mihir ShahDirector31 Mar 201511 Years 7 MonthsCurrent
Yogesh Kantilal VariaDirector28 May 20215 Years 5 MonthsCurrent
Vijaykumar Shivaji AyareDirector10 Feb 20251 Years 9 MonthsCurrent
Mihir Prakash ShahManaging Director05 Jul 20242 Years 4 MonthsCurrent
Binoy Baiju ShahDirector05 Jul 20242 Years 4 MonthsCurrent
Harish Sunderlal PanpaliaDirector11 Aug 20233 Years 3 MonthsCurrent

Peer comparison

Parnax Lab Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Parnax Lab Limitedthis company₹248.54 Cr (FY 2026)₹12.8 Cr5.2%32.4%Mumbai, Maharashtra, India
Galentic Pharma India Pvt Ltd₹195.24 Cr (FY 2025)56.0%Mumbai, Maharashtra, India
Therachem Research Medilab (India) Private Limited₹194.12 Cr (FY 2023)-7.0%Jaipur, Rajasthan, India
Sriram Healthcare Private Limited₹192.28 Cr (FY 2025)-8.0%Kasauli, Himachal Pradesh, India
Regenix Drugs Limited₹188.37 Cr (FY 2024)9.0%Chennai, Tamil Nadu, India
Goldencross Pharma Limited₹187.87 Cr (FY 2025)31.0%Mumbai, Maharashtra, India
Comed Chemicals Limited₹187.35 Cr (FY 2025)12.0%Vadodara, Gujarat, India
Mapra Laboratories Pvt Ltd₹184.45 Cr (FY 2025)5.0%Mumbai, Maharashtra, India

To see the full peer comparison of Parnax Lab Limited, buy the company report.

Auditor

Parnax Lab Limited is audited by M/s. C.N.Patel & Co for the financial year 2022.

Auditor firmFinancial yearFirm registration number
M/s. C.N.Patel & CoFY 2022112552W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 72.30%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 27.70%.

Promoters: 72.30%Retail & Others: 27.70%
Sep 2026
QUARTER
72.30% Promoters
27.70% Retail & Others
Promoter holding - history
Now 72.30% · Sep 2026High 72.30% · Dec 2025Low 72.30% · Dec 2025
71%71.8%72.5%73.3%74%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 72.30%Mar 2026: 72.30%Jun 2026: 72.30%Sep 2026: 72.30%72.30%72.30%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters72.30%72.30%72.30%72.30%
Public27.70%27.70%27.70%27.70%

Charges & borrowings

Open charges
₹24.2 Cr
Satisfied charges
₹4.66 Cr
Breakdown by lending institutions
State Bank of India₹24.20 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
07 Sep 200290165470State Bank of India₹10.39 CrOpen
30 Mar 200080031525State Bank of India₹2.72 CrOpen
30 Mar 200090350040State Bank of India₹10.39 CrOpen
04 May 199590163159State Bank of India₹26 LakhOpen
04 May 199590165134State Bank of India₹26 LakhOpen

To see the full charge records of Parnax Lab Limited, buy the company report.

Total charge records: 9 View all charges

Deals & funding

Parnax Lab Limited has 150 deals on record (148 market trades, 2 funding rounds), with disclosed funding of ₹24.01 Cr; the latest was in March 2022.

Total deals
150
Market trades
148
Funding rounds
2
Disclosed funding
₹24.01 Cr

Deals on record (5 of 150)

WhenDealAmountParties
Apr 2017Market trade₹57.8 LakhBuyer: Setu Securities Private Limited
Seller: Setu Securities Private Limited
Apr 2017Market trade₹1.25 CrBuyer: Setu Securities Private Limited
Apr 2017Market trade₹61.6 LakhBuyer: Setu Securities Private Limited
Jan 2016Market trade₹39.2 LakhSeller: Digital Biotech Private Limited
Dec 2015Market trade₹98.7 LakhBuyer: Digital Biotech Private Limited

To see the full deal history of Parnax Lab Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Parnax Lab Limited has 14 MSME Form 1 returns on record between 2019 and 2024, listing 283 overdue payments to 41 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 41)

SupplierAmount dueDue sinceReported on
an individual supplier
an individual supplier
an individual supplier
an individual supplier
an individual supplier

To see the full MSME payment records of Parnax Lab Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Parnax Lab has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Naxpar Pharma Private LimitedU52310MH2004PTC144449

To see the full group structure of Parnax Lab Limited, buy the company report.

GST

Parnax Lab has 3 GST registrations: 2 active and 1 cancelled or inactive.

Total GSTINs
3
Active
2
Cancelled / inactive
1
GSTINStateStatusRegistered on
27AAACK1457E1ZTMaharashtraActive01 Jul 2017
26AAACK1457E2ZUDadra and Nagar Haveli and Daman and DiuActive24 Nov 2017

To see the full GST registrations and return filing status of Parnax Lab Limited, buy the company report.

Recent activity

Parnax Lab Limited has 32 board changes on record since 1997: 19 appointments and 13 cessations. The latest: Tirunillai Venkateswara Anantharaman ceased to be Director on 30 Mar 2025.

Filing
Parnax Lab Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
AGM
Parnax Lab Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Ceased
Tirunillai Venkateswara Anantharaman ceased to be Director.
Appointed
Vijaykumar Shivaji Ayare was appointed as Director.
Ceased
Baiju Mahasukhlal Shah ceased to be Managing Director.
Appointed
Binoy Baiju Shah was appointed as Director.
Appointed
Mihir Prakash Shah was appointed as Managing Director.
Ceased
Prakash Mahasukhlal Shah ceased to be Director.
Charges
A charge registered on 31 Mar 2018 via Charge ID 100168004 with Others was fully satisfied on 18 Jun 2024.
Ceased
Vinayak Babli Desai ceased to be Director.
Appointed
Harish Sunderlal Panpalia was appointed as Director.
Appointed
Yogesh Kantilal Varia was appointed as Director.

40 earlier events are in the company report.

Frequently asked questions

Parnax Lab is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 August 1982 (44+ years old) and is registered under CIN L36912MH1982PLC027925. Listed on BSE: 506128 and NSE: PARNAXLAB.

Parnax Lab reported revenue of ₹248.54 Cr for FY 2025-26 (up 32.4% YoY) based on consolidated financials.

Parnax Lab has 6 current directors:

The latest financial statements of Parnax Lab on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Parnax Lab is 27AAACK1457E1ZT, registered in Maharashtra. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 26AAACK1457E2ZU (Dadra and Nagar Haveli and Daman and Diu).

The CIN (Corporate Identification Number) of Parnax Lab is L36912MH1982PLC027925. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Parnax Lab is a listed company as per MCA records. Its shares are listed on both BSE (code: 506128) and NSE (symbol: PARNAXLAB).

Parnax Lab has 1 court case on record: 1 filed by the company.

Parnax Lab was incorporated on 03 August 1982, making it 44+ years old. It is registered with the Registrar of Companies, Mumbai.

Parnax Lab has 150 deals on record (148 market trades, 2 funding rounds), with disclosed funding of ₹24.01 Cr; the latest was in March 2022.

The peers of Parnax Lab by revenue are Galentic Pharma India Pvt Ltd, Therachem Research Medilab (India) Private Limited, Sriram Healthcare Private Limited, Regenix Drugs Limited, Goldencross Pharma Limited and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Tirunillai Venkateswara Anantharaman ceased to be Director on 30 Mar 2025. Vijaykumar Shivaji Ayare was appointed as Director on 10 Feb 2025. Baiju Mahasukhlal Shah ceased to be Managing Director on 05 Jul 2024. Parnax Lab has 32 board changes on record in total.